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Abstract: Background: The sustainable use of HAART within the sub-Saharan and other developing world settings faces 
the emerging challenge of drug resistance. Nucleoside reverse transcriptase inhibitors (NRTI) form the backbone of 
HAART and preserving their “antiviral efficacy” is thus critical to sustainable HAART use. 
Methods: A systematic review of the “mechanisms of evolution” of resistance to NRTI at the HIV genome level, and the 
phenotypic manifestations on drug pharmacokinetics was done. 
Conclusion: This paper provides an evidence based account of how the knowledge of pharmacogenomics may be ex-
ploited to tackle NRTI resistance within limited resource. 
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INTRODUCTION 
  The highest burden of the human immunodeficiency vi-
rus (HIV) epidemic is concentrated in the sub-Saharan re-
gion. Over 70% of all global HIV infections have been found 
to occur here [1]. Despite the earlier policy and patent con-
troversies surrounding the use of highly active antiretroviral 
therapy (HAART) within this setting, HAART has widely 
gained application here [2]. This access to HAART can be 
mainly attributed to several advocacy and funding avenues 
[2-4]. Specifically, the World Bank and its global partners, in 
particular, with commitment by the G8, have ensured that 
several countries within this setting can meet the WHO 3’by 
5” target of treating 3 million by 2005 [3,4]. Through Initia-
tive such as the global Fund to Fight AIDS, TB and Malaria-
GFATM, the President's Emergency Plan for AIDS Relief 
(PEPFAR) and several others, about 2 million persons living 
with HIV/AIDS are accessing HAART today [2, 3]. The 
evolution of resistance however poses one of the biggest 
challenges to HAART use here. Developing mechanisms to 
curtail its growing prevalence amidst the existent limited 
resources may be more cost effective and realistic than wait-
ing to deal with an outright “outbreak” of resistant virus. 
One way to do so is by ensuring that all persons living with 
HIV or the Acquired Immunodeficiency Syndrome (AIDS): 
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PLWHA on HAART take their medications in the right dos-
ages and at the right time. This is because non compliance is 
one of the major factors that influence the evolution of resis-
tance [5]. The second option would be to develop the neces-
sary capacity for monitoring drug sensitivity and profiling 
resistance. The latter option has however remained widely 
unavailable at several of the HIV/AIDS treatment and care 
centers- mainly due to the high costs that are involved in 
phenotyping and genotyping HIV resistance to HAART [2]. 
To ensure the success of the HAART programs in this set-
ting however, the capacity to deal with resistance to HAART 
is needed as an integral part of the HIV treatment and care 
systems here, emphasizing why global partners in the fight 
against the HIV epidemic should consider a focused look at 
the subject. The third option that is widely explored else-
where but is still limited in the developing world is the use of 
“salvage regimens” [6]. 
  Amidst the above available options, until such a time 
when capacity for resistance profiling and access to equally 
diverse options for “salvage therapy” become readily avail-
able in this setting, it is the responsibility of both the 
PLWHA and the respective primary care physicians to work 
together so as to preserve current first line HAART options 
from resistance. Several compliance studies have shown that 
sub-Saharan PLWHA are doing their part relatively well in 
terms of compliance to HAART [5]. 
  Physicians, through knowledge of HAART pharmacoge-
nomics, specifically, the effects of individual resistance phe-
notypes on overall HAART pharmacodynamics (PD) and Harnessing Pharmacogenomics to Tackle Resistance  The Open AIDS Journal, 2008, Volume 2    79 
pharmacokinetics (PK), may equally play a significant part 
in setting a barrier to the evolution of resistance to first line 
HAART options. By so doing, they can as well devise vi-
rologically effective options for “salvage therapy” from the 
limited options of HAART available. Today, according to 
the International AIDS Society, the ideal combination of 
HAART should comprise a backbone of two NRTIs plus 
either a Protease Inhibitor or a Non-NRTI (NNRTI). NRTIs 
thus form a significant component of HAART whose func-
tion should be jealously “guarded” to ensure sustainable use 
of any selected HAART regimen or combination. This paper 
aims to examine how “evolution of resistant phenotypes and 
genotypes to NRTI (and NNRTI) influences the general PD 
and PK of HAART”. From that examination, we hope to 
provide an evidence based account of how knowledge of this 
“pharmacogenomics” may be applied in resource limited 
setting to prevent or delay the evolution of resistance to 
HAART while maintaining virologic suppression among 
those with identified resistance. 
GENERAL CONCEPT OF HOW RESISTANCE 
EMERGES IN HAART AND ITS IMPLICATION ON 
FIGHTING RESISTANCE TO HAART 
1. The Evolution of Resistance to HAART: A Genomic 
Perspective 
  Drug resistance to HAART in general results from muta-
tions in the viral genome [6]. Specifically, those mutations 
associated to HAART resistance are localized on those genes 
that encode the molecular targets of antiretroviral drugs. 
Hence resistance to NRTI/NNRTI, Protease inhibitors (PIs) 
and fusion inhibitors can be localized on reverse tran-
scriptase, protease, and glycoprotein41 respectively. Well as 
these mutations have been noted to occur spontaneously in 
the HIV genome, and resistant phenotypes exist even prior to 
the use of HAART (implying that the use of HAART in it-
self does not select for resistant virus)[6], it has equally been 
observed that the propagation and maintenance of these re-
sistant or mutant viruses is largely favored by sub-optimal 
plasma inhibitory concentrations (PIC) of the HAART com-
ponent to which resistance exists. The latter serves to kill off 
the non resistant viruses (which are still susceptible to the 
combination of HAART in use) and leaves the mutant to 
shrive. In general, for any organism or pathogen- the muta-
tion rate is a dependant on three factors: (a) Presence of an 
outside selective pressure-which for microbes like HIV is 
often a drug that is present at lower than minimal inhibitory 
or lethal dosages to the microbe (b) frequency of replication 
or duplication of the microbe and (c) efficacy of the proof 
reading mechanisms of the process of DNA or RNA synthe-
sis during replication. Because of the rapid replication rate of 
HIV (where the virus produces 10
10 billion copies every 24 
hours), and the error prone reading mechanism of the RNA 
polymerase relative to its DNA counterpart (DNA polym-
erase), HIV is inherently highly susceptible to variations in 
the genotypes; meaning that even the slightest pressure from 
a misuse of drug combinations is likely to result into the evo-
lution of resistance due to an” inherent narrow viral resis-
tance barrier” [6, 7]. 
2. Phenotypic Manifestation of Resistant Genotypes and 
the Mechanisms of Resistance 
  Most NRTI are analogues of deoxynucleoside triphos-
phates (dNTs) that are integrated into the DNA (or RNA) 
chain in the same way that normal dNTs are during the proc-
esses of DNA or RNA synthesis. However, because of al-
terations in the configuration of the NRTIs, NRTIs can not 
be processed further by the DNA or RNA synthesizing en-
zymes_ (DNA polymerase and RNA polymerase respec-
tively). This results into premature termination of the nucleo-
tide chain synthesis, thus respective cell proliferation [6]. 
NRTIs specifically target function of viral reverse tran-
scriptase enzyme. Two Mechanism of resistance against re-
verse transcriptase inhibitors are known. These are: 
1.  Discrimination: This occurs when the reverse tran-
scriptase (RT) enzyme develops the ability to evade 
binding of the NRTI or NNRTI but retains its ability 
to bind the natural deoxynucleoside triphosphates 
substrates. Point mutations such as K65R and M184V 
are associated with this phenotype [6]. 
2.  Pyrophosphoroylation: This involves an increased 
phosphorolytic removal of the chain terminating 
NRTI from the 3’end of the primer after it has been 
integrated into viral DNA strand. This mechanism, 
that is also called “primer unblocking” or “excision” 
is mainly associated with thymidine analogue muta-
tions (TAMs) selected for by Stavudine and Zi-
dovudine (M41L, T215Y/F and K218Q/E) [6,7]. 
  Although different drugs select for different mutations 
associated with different resistance profiles or mechanisms, 
what is of clinical significance in dealing with resistant virus 
is how the evolution of resistant phenotypes may be avoided, 
or dealt with. 
  To do so, we find that one needs to appreciate the phar-
macogenomics of HAART resistance, particularly (1) what 
mutations (genotypes) are associated with misuse of particu-
lar NRTIs (or their combinations) and (2) the possible bene-
ficial effects of those resultant phenotypes on the PK and PD 
of other HAART components. 
PHENOTYPIC MANIFESTATIONS OF RESISTANT 
GENOTYPES ASSOCIATED WITH SPECIFIC NRTI 
(OR COMBINATION OF NRTIS) OF RELEVANCE 
TO DEALING WITH RESISTANCE IN RESOURCE 
LIMITED SETTINGS 
 Three  main  “combinations of two “NRTIs” have gained 
wide usage globally as backbones in HAART; and are 
equally used within the sub-Saharan setting. These are Teno-
fovir/Emtricitabine (Truvuda), Zidovudine/lamivudine 
(combivir) and Abacavir/lamivudine (Kivexa)[2]. Most other 
combinations used as backbones involve an interchange of 
the individual drugs in these three. When virologic failure is 
observed in patients using any of these, it may be due to re-
sistance to a single component of HAART or all. To note is 
that: some drug combinations are associated with “much 
narrower resistance barrier than others. In addition, while the 
occurrence of a “single mutation” may suffice to confer re-
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as is the case with M184V/L74V for lamivudine (3TC) and 
Emtricitabine (FTC); other drugs such as Zidovudine (AZT) 
and Stavudine (d4T) have a broader barrier to resistance and 
an accumulation of “resistance mutations” must occur for 
phenotypic resistance to manifest [6]. In any patient on a 
specified combination of HAART, various populations of 
mutant viruses with differing susceptibility to individual 
drug components of the HAART regimens co-exist. Some of 
these mutant genotypes such as several Thymidine Analogue 
Mutations (TAMs) may confer resistances to all members of 
the group as related above, while some resistant genotypes 
are only associated with resistance to a single member of the 
group such as the signature mutations of Tenofovir(K65R); 
with limitations the two mutations M184V and L74V that 
are often associated with sub-optimal use of and lamivudine 
and Abacavir [8-10]. Specifically, while the insertions in 
codon 69 and 70(T69) has been found to be associated with a 
high resistance to ZDV, d4T, ddI, ABC and TDF [11-13], 
the mutation in the conserved domain of RT-Q151M; whose 
occurrence has been associated with two drug therapy_ dida-
nosine with either Zidovudine or Stavudine( which is a rare 
scenario in modern HAART combining 3 drugs) confers 
resistance to all NRTIs [13]. Some mutations associated with 
resistance to certain drugs such as the K65R and M184V 
mutations for Tenofovir and Lamivudine/Abacavir respec-
tively have been found to confer an increased susceptibility 
to other NRTIs like Zidovudine [11,12]. In other words, 
while predominance of some mutants associated with resis-
tance to a given single member of the NRTI-backbone con-
fers resistance to all members of the group, some mutants are 
associated with phenotypic manifestations that confer an 
increased susceptibility to another NRTI. The significance of 
these points above when dealing with clinical resistance to 
HAART in a resource limited setting is discussed below. 
EXPLOITING NRTI RESISTANCE PHARMACOGE-
NOMICS TO PREVENT THE EVOLUTION OR DEAL 
WITH EXISTENT NRTI RESISTANCE IN A RE-
SOURCE POOR SETTINGS 
 Marcelin  AG  et al. [6] and others have provided a critical 
review of the phenotypic manifestations of NRTI resistance 
genotypes [9-18], the fitness between mutant and wild type 
viruses [6], and inherent “resistance barriers” for individual 
NRTIs [9-18]. Specifically, the review by Marcelin AG et al. 
[6] reveals a number insight into the beneficial “pharma-
cokinetics” of NRTI resistance which may be applied to pro-
long HAART sustainability in resource limited settings by 
improving the general outcome of NRTIs. These benefits are 
and can be accrued as detailed in the three scenarios here. 
 First, using high resistance barrier first line combinations 
(while avoiding those with low resistance barriers); it is pos-
sible to delay the emergence of resistant mutants to an 
HAART combination. This serves the purpose of preserving 
future options. For instance, lets consider the 3TC/FTC plus 
thymidine analogues scenario. It has been noted that the sys-
tematic use of 3TC/FTC plus thymidine analogues have the 
advantage of low resistance mutations and associated vi-
rologic failure, and its use may serve to preserve future op-
tions. In so doing, there is however need to avoid prolonged 
viral replication by using either a NNRTI or Protease inhibi-
tor (PI) in addition [2, 9]. Another scenario is that of 
ABC/3TC plus NRTI with NNRTI or PI. This combination 
of NRTIs similarly serves the purpose of preserving future 
options as the evolution of the M184V resistance mutation to 
Abacavir(ABC) serves to increase susceptibility to 
NRTIs(specifically Zidovudine) while L74V mutation com-
monly associated with lamivudine misuse only affects dida-
nosine(ddI) among the NRTIs. The lowest mutation rates 
have been observed when this backbone combination of 
ABC/3TC is used in combination with PIs [14]. Lastly, 
avoiding didanosine with other thymidine analogues is criti-
cal, since when thymidine analogues such as Zidovudine 
(ZDV) and Stavudine (d4T) are used in combination with 
didanosine, a high rate of thymidine analogue mutations 
(TAMs) is seen with failure, many of which confer cross 
resistance to other NRTIs. When used in isolation, dida-
nosine selects for L74V mutation and more rarely the K65R 
[6, 15-17]. While the presence of L74V only affects ddI, 
when associated with other mutations such as TAMS, L74V 
confers resistance to TDF and ABC [6]. 
 Second, by exploring interactive co-potentiation that 
some mutants associated with resistance to a particular drug 
confer to in situ bioavailability and viral susceptibility to 
another, it is possible to enhance viral suppression. One such 
example is use of TDF with NRTIs. When Tenofovir (TDF) 
is used in a patient on NRTIs in whom prior TAMs have 
evolved, the TDF signature mutation K65R emerges [10-13]. 
However, K65R has the antagonistic effect of reducing the 
excision process induced by TAMs (thus associated resis-
tance to NRTIs). In addition, biochemical studies have 
shown a similar antagonism between K65R and L74V that is 
correlated with a poor ability of the mutant viruses with the 
double RT resistance mutations “K65R+L74V” to use natu-
ral nucleosides relative to wild types [11-13]. As another 
example, in using 3TC/FTC with Zidovudine, it has been 
shown that changes in the reverse transcriptase enzyme asso-
ciate with the resistant mutation to Lamivudine increases the 
fidelity and diminished processivity of the viral reverse tran-
scriptase enzyme), an effect that serves to decrease resistant 
viral fitness [18]. When present with Zidovudine associated 
mutations, M184V however has been found to equally serve 
to partially restore Zidovudine (ZDV) efficacy and reduce 
the emergence of TAMs [18, 19]. This combination of re-
duced “resistant virus fitness” and increased susceptibility to 
ZDV restores virologic efficacy of the HAART combination 
containing 3TC/FTC plus Zidovudine. Lastly, since exposure 
to sub-optimal plasma inhibitory concentrations of HAART 
is the main exogenous selective pressure leading to evolution 
of resistant mutants and wild type virus is relatively more fit 
than mutant virus in the absence of HAART induced inhibi-
tion or suppression, removing “drug” pressure will serve to 
create an environment in which wild type virus out compete 
mutant (resistant) virus_ “survival of fittest” [6]. Drug holi-
days may thus have a role to play in the management of per-
sons living with HIV/AIDS who develop resistance to major 
NRTI options for HAART combinations within resource 
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LIMITATIONS OF THESE GUIDELINES: AN UN-
CERTAIN FUTURE 
  Most of the conclusions made here have been drawn 
from clinical trial observations [2, 6, 9-18]. With a prolonged 
use of HAART and evolution of patterns of resistance not 
currently documented; the standard of care is bound to 
change. A continued surveillance of the prevailing patterns 
of resistance mutations, say at a central laboratory, may 
serve to inform the decision on whether or not these guide-
lines can still be “generally” applicable. 
WAY FORWARD 
  Amidst the general lack of resistance phenotyping and 
genotyping, and limited options for salvage therapy, a mini-
mal but clinically relevant knowledge of the “beneficial in-
teractive phenotypic manifestations of NRTI resistance 
genotypes, the variation in fitness between mutant and wild 
type viruses, and inherent “resistance barriers” for individual 
NRTIs” is critical for primary health care providers using 
HAART to treat and care for persons living with HIV or 
AIDS (PLWHA) in resource poor settings to ensure a sus-
tainable use of HAART. A summary of the forwarded op-
tions for dealing with NRTI resistance in resource poor set-
tings is shown in Table 1. 
Table 1.   
 
A. Using high resistance barrier first line combinations (while avoid-
ing those with low resistance) to delay the emergence of resistant 
mutants to an HAART combination 
1. Using Lamivudine/ Emtricitabine plus a thymidine analogue to pre-
serving future option 
2. Using Abacavir/Lamivudine with NRTI plus NNRTI or PI 
3. Avoiding Abacavir/Lamivudine (Kivexa) plus Tenofovir 
4. Avoiding Zidovudine analogues with didanosine 
B. Exploring interactive co-potentiation that some mutants associ-
ated with resistance to a particular drug confer to in situ bioavail-
ability and viral susceptibility to another 
1. Tenofovir with NRTIs other than abacavir/lamivudine 
2. Lamivudine/Emtricitabine with Zidovudine 
C. Drug holidays for selective elimination of resistant virus 
 
CONCLUSION 
  Knowledge of the pharmacogenomics of NRTI may be 
explored to prevent resistance in resource limited settings. 
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